(Q34372972)

1 August 2017

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma (English)

1 reference

1 August 2017

phase I clinical trial

0 references

0 references

0 references

0 references

Andrea B Troxel

12

0 references

Katherine L Nathanson

15

object named as

Katherine L Nathanson

1 reference

1 August 2017

Reshma Rangwala

1

1 reference

1 August 2017

Robert Leone

2

1 reference

1 August 2017

Yunyoung C Chang

3

1 reference

1 August 2017

Leslie A Fecher

4

1 reference

1 August 2017

Lynn M Schuchter

5

1 reference

1 August 2017

Amy Kramer

6

1 reference

1 August 2017

Kay-See Tan

7

1 reference

1 August 2017

Daniel F Heitjan

8

1 reference

1 August 2017

Glenda Rodgers

9

1 reference

1 August 2017

Maryann Gallagher

10

1 reference

1 August 2017

Shengfu Piao

11

1 reference

1 August 2017

Tracey L Evans

13

1 reference

1 August 2017

Angela M DeMichele

14

1 reference

1 August 2017

Peter J O'Dwyer

16

1 reference

1 August 2017

Jonathon Kaiser

17

1 reference

1 August 2017

Laura Pontiggia

18

1 reference

1 August 2017

Lisa E Davis

19

1 reference

1 August 2017

Ravi K Amaravadi

20

1 reference

1 August 2017

20 May 2014

1 reference

1 August 2017

1 reference

1 August 2017

10

1 reference

1 August 2017

8

1 reference

1 August 2017

1369-1379

1 reference

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Effect of temozolomide on the U-118 glioma cell line

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Temozolomide and unusual indications: review of literature.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Pancreatic cancers require autophagy for tumor growth

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Principles and current strategies for targeting autophagy for cancer treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

The history and future of chemotherapy for melanoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4203514

Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FAUTO.29118

Induction of autophagy in temozolomide treated malignant gliomas.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FAUTO.29118

Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.4161%2FAUTO.29118

21 January 2018

Identifiers

DOI

10.4161/AUTO.29118

1 reference

1 August 2017

1 reference

1 August 2017

1 reference